Xilio Therapeutics XLO
NASDAQ XLO
$8.47 -0.06 (-0.70%)
At close: Nov 11, 2026 · 4:00 PM EST

Xilio Therapeutics (XLO) Receivables (2024 - 2025)

Updated

Xilio Therapeutics (XLO) reported Receivables of $30 million for Q1 2024.

Analysis

Xilio Therapeutics (XLO) Receivables (2024 - 2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 25.23 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 18.99 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 13.51 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 12.74 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 16.16 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 10.35 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 5.01 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 14.19 Bn
10 Xilio Therapeutics 167.94 Mn -378.15 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 17.50 Mn
Mar 31, 2024 30.00 Mn
API Access

Xilio Therapeutics Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables&ticker=XLO&period=max&api_key=YOUR_API_KEY